论文部分内容阅读
目的评价异环磷酰胺(IFO).VP-16.DDP加放疗治疗晚期非小细胞肺癌疗效及毒副作用观察。方法化疗用IEP化疗方案,异环磷酰胺(IFO)1.2g/m2静脉滴注,第1~5天,美司纳400mg,用IFO的同时,第0、4.8h静脉推注,第1~5天;vp-16100mg静脉滴注,第1~5天,顺铂(DDP)70mg/m2静脉滴注,第1~5天以上方案3~4周为1个周期,化疗3个周期,化疗结束后2~3个周为轻底胃肠反应、骨髓抑制、脱发、轻度肝功能损害。期开始放疗。放射治疗采用X线加速器体外照射。照射也包括原发灶、同侧肺门、全纵隔或锁骨上淋巴结及远处转移灶。放射剂量为50~70Cy,每2Cy,每周5次,5~7周完成。照射剂量可根据患者一般情况和病理类型适当增减。全部病例中CR9例,其中7例为鳞癌,2例为低分化腺癌,有效率20.93%;PR19例,其中11例为鳞癌,8例为低分化腺癌,有效率47.6%,总有效率65.11%。毒副作用为轻底胃肠反应、骨髓抑制、脱发、轻度肝功能损害。结论异环磷酰胺(IFO).VP-16.DDP加放疗治疗晚期非小细胞肺癌疗效较好,毒副反应可以耐受,值得临床推广。
Objective To evaluate the efficacy and toxicity of ifosfamide (IFO) .VP-16.DDP plus radiotherapy in the treatment of advanced non-small cell lung cancer. Methods chemotherapy with IEP chemotherapy, ifosfamide (IFO) 1.2g / m2 intravenous drip, the first to 5 days, the United States Division satisfied 400mg, with IFO at the same time, the first 0,4.8h intravenous injection, 5 days; vp-16100mg intravenous drip, the first to 5 days, cisplatin (DDP) 70mg / m2 intravenous drip, the first 5 days above the program for 3 to 4 weeks for a cycle of three cycles of chemotherapy, chemotherapy 2 to 3 weeks after the end of the light-phase gastrointestinal reactions, bone marrow suppression, hair loss, mild liver damage. Period began radiotherapy. Radiotherapy using X-ray accelerator in vitro irradiation. Irradiation also includes primary tumor, ipsilateral hilar, total mediastinal or supraclavicular lymph nodes and distant metastases. Radiation dose of 50 ~ 70Cy, every 2Cy, 5 times a week, 5 to 7 weeks to complete. Irradiation dose according to the general situation and pathological types of patients appropriate changes. In all cases CR9 cases, of which 7 cases of squamous cell carcinoma, 2 cases of poorly differentiated adenocarcinoma, the effective rate of 20.93%; PR19 cases, of which 11 cases of squamous cell carcinoma, 8 cases of poorly differentiated adenocarcinoma, the effective rate was 47.6%, total Effective 65.11%. Toxic side effects of light-phase gastrointestinal reactions, bone marrow suppression, hair loss, mild liver damage. Conclusion ifosfamide (IFO) .VP-16.DDP plus radiotherapy in the treatment of advanced non-small cell lung cancer has good curative effect and toxic side effects, which is worthy of clinical promotion.